Czirr James C's Form 4 filing
Galectin Therapeutics IncGALT · filed Dec 18, 2025
- Accession no.
- 0001493152-25-028303
- Filed
- Dec 18, 2025, 10:34 AM ET
- Trade date
- Nov 24-Dec 16, 2025
- Filing delay
- 24 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $204.3K. It was filed 24 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Czirr James CCIK 0001260641 | 10% Owner |
| 10X Fund, L.P.CIK 0001453356 | 10% Owner |
| 10X Capital Management, LLCCIK 0001457247 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.